



Ecuador



Category Scores




Overall Score in Comparison





Ecuador



Key Areas of Strength

- Strengthened support for SMEs through WIPO-WEF "Inventor Assistance Program"
- National IP authority SENADI ordered local ISPs to disable access to several websites hosting infringing and unlicensed content
- Five-year term of RDP defined in law Código Ingenios
- Limited re-criminalization of IP rights through 2016 criminal law amendments
- Member of PPH

Key Areas of Weakness

- No special IP incentives for orphan medicinal product development
- Implementing regulations potentially undermine *Código Ingenios* RDP term of protection
- Plant variety protection term is shorter than internationally accepted term
- Substantial barriers are in place for licensing activities, including direct government intervention and review of technology transfer and licensing agreements
- Key life sciences IP rights are missing, including patent term restoration and mechanisms for early patent dispute resolution
- Código Ingenios imposes additional limits on patentability and amount of nonpatentable subject matter
- Persistently high levels of piracy; estimated 68% software piracy rate
- Ecuador has a low score for its participation in and ratification of international treaties

Indicator	Score
Category 1: Patents Rights and Limitations	2.99
1. Term of protection	1.00
2. Patentability requirements	0.50
3. Patentability of CIIs	0.00
4. Plant variety protection	0.74
5. Pharmaceutical-related enforcement	0.00
Legislative criteria and use of compulsory licensing	0.00
7. Pharmaceutical patent term restoration	0.00
8. Membership of a Patent Prosecution Highway	0.50
9. Patent opposition	0.25
Category 2: Copyrights and Limitations	1.74
10. Term of protection	0.74
11. Exclusive rights	0.25
12. Expeditious legal remedies disabling access to infringing content online	0.25
13. Cooperative action against online piracy	0.00
14. Limitations and exceptions	0.25
15. TPM and DRM	0.25
16. Government use of licensed software	0.00
Category 3: Trademarks Rights and Limitations	1.75
17. Term of protection	1.00
18. Protection of well-known marks	0.25
19. Exclusive rights, trademarks	0.25
20. Frameworks against online sale of counterfeit goods	0.25
Category 4: Design Rights and Limitations	0.90
21. Industrial design term of protection	0.40
22. Exclusive rights, industrial design rights	0.50
Category 5: Trade Secrets and the Protection of	
Confidential Information	1.00
23. Protection of trade secrets (civil remedies)	0.25
24. Protection of trade secrets (criminal sanctions)	0.25
25. Regulatory data protection term	0.50
Category 6: Commercialization of IP Assets	0.50
26. Barriers to market access	0.00
27. Barriers to technology transfer	0.25
28. Registration and disclosure	
requirements of licensing deals	0.00

Indicator	Score
29. Direct government intervention	0.00
in setting licensing terms	0.00
30. IP as an economic asset31. Tax incentives for the creation of IP assets	0.25 0.00
31. Tax incentives for the creation of IP assets	0.00
Category 7: Enforcement	1.66
32. Physical counterfeiting rates	0.34
33. Software piracy rates	0.32
34. Civil and precedural remedies	0.25
35. Pre-established damages	0.25
36. Criminal standards	0.25
37. Effective border measures	0.00
38. Transparency and public reporting by customs	0.25
Category 8: Systemic Efficiency	2.25
39. Coordination of IP rights enforcement	0.25
40. Consultation with stakeholders	
during IP policy formation	0.25
41. Educational campaigns and awareness raising	0.75
42. Targeted incentives for the creation and use of IP assets for SMEs	0.75
43. IP-intensive industries, national economic impact analysis	0.05
economic impact analysis	0.25
Category 9: Cutting-Edge Innovation	0.25
Category 9: Cutting-Edge Innovation	
Category 9: Cutting-Edge Innovation 44. IP incentives for orphan medicinal	0.00
 Category 9: Cutting-Edge Innovation 44. IP incentives for orphan medicinal product development 45. IP incentives for orphan medicinal product development, term of protection 46. Restrictions on the effective use 	0.00
Category 9: Cutting-Edge Innovation 44. IP incentives for orphan medicinal product development 45. IP incentives for orphan medicinal product development, term of protection	0.00
 Category 9: Cutting-Edge Innovation 44. IP incentives for orphan medicinal product development 45. IP incentives for orphan medicinal product development, term of protection 46. Restrictions on the effective use of existing IP incentives for orphan medicinal product development Category 10: Membership and Ratification 	0.00 0.00 0.00
 Category 9: Cutting-Edge Innovation 44. IP incentives for orphan medicinal product development 45. IP incentives for orphan medicinal product development, term of protection 46. Restrictions on the effective use of existing IP incentives for orphan medicinal product development 	0.00 0.00 0.00
Category 9: Cutting-Edge Innovation 44. IP incentives for orphan medicinal product development 45. IP incentives for orphan medicinal product development, term of protection 46. Restrictions on the effective use of existing IP incentives for orphan medicinal product development Category 10: Membership and Ratification of International Treaties 47. WIPO Internet Treaties	0.00 0.00 0.00
 Category 9: Cutting-Edge Innovation 44. IP incentives for orphan medicinal product development 45. IP incentives for orphan medicinal product development, term of protection 46. Restrictions on the effective use of existing IP incentives for orphan medicinal product development Category 10: Membership and Ratification of International Treaties 	0.00 0.00 0.00 0.00
 Category 9: Cutting-Edge Innovation 44. IP incentives for orphan medicinal product development 45. IP incentives for orphan medicinal product development, term of protection 46. Restrictions on the effective use of existing IP incentives for orphan medicinal product development Category 10: Membership and Ratification of International Treaties 47. WIPO Internet Treaties 48. Singapore Treaty on the Law of Trademarks and Protocol Relating to the Madrid Agreement 	0.00 0.00 0.00 0.00 2.00 1.00
 Category 9: Cutting-Edge Innovation 44. IP incentives for orphan medicinal product development 45. IP incentives for orphan medicinal product development, term of protection 46. Restrictions on the effective use of existing IP incentives for orphan medicinal product development Category 10: Membership and Ratification of International Treaties 47. WIPO Internet Treaties 48. Singapore Treaty on the Law of Trademarks and Protocol Relating to the Madrid Agreement Concerning the International Registration of Marks 	0.00 0.00 0.00 2.00 1.00
 Category 9: Cutting-Edge Innovation 44. IP incentives for orphan medicinal product development 45. IP incentives for orphan medicinal product development, term of protection 46. Restrictions on the effective use of existing IP incentives for orphan medicinal product development Category 10: Membership and Ratification of International Treaties 47. WIPO Internet Treaties 48. Singapore Treaty on the Law of Trademarks and Protocol Relating to the Madrid Agreement Concerning the International Registration of Marks 49. Patent Law Treaty and Patent Cooperation Treaty 50. Membership of the International Convention for the Protection of New Varieties of Plants, act of 1991 51. Membership of the Convention 	0.00 0.00 0.00 2.00 1.00 0.00 0.50
 Category 9: Cutting-Edge Innovation 44. IP incentives for orphan medicinal product development 45. IP incentives for orphan medicinal product development, term of protection 46. Restrictions on the effective use of existing IP incentives for orphan medicinal product development Category 10: Membership and Ratification of International Treaties 47. WIPO Internet Treaties 48. Singapore Treaty on the Law of Trademarks and Protocol Relating to the Madrid Agreement Concerning the International Registration of Marks 49. Patent Law Treaty and Patent Cooperation Treaty 50. Membership of the International Convention for the Protection of New Varieties of Plants, act of 1991 51. Membership of the Convention on Cybercrime, 2001 52. The Hague Agreement Concerning the 	0.00 0.00 0.00 2.00 1.00 0.50 0.00 0.00
 Category 9: Cutting-Edge Innovation 44. IP incentives for orphan medicinal product development 45. IP incentives for orphan medicinal product development, term of protection 46. Restrictions on the effective use of existing IP incentives for orphan medicinal product development Category 10: Membership and Ratification of International Treaties 47. WIPO Internet Treaties 48. Singapore Treaty on the Law of Trademarks and Protocol Relating to the Madrid Agreement Concerning the International Registration of Marks 49. Patent Law Treaty and Patent Cooperation Treaty 50. Membership of the International Convention for the Protection of New Varieties of Plants, act of 1991 51. Membership of the Convention on Cybercrime, 2001 	0.00 0.00 0.00 2.00 1.00 0.00 0.50

Percentage of Overall Score: 27.91%

Total Score: 14.79

•

Spotlight on the National IP Environment

Past Editions versus Current Score

Ecuador's overall score remains unchanged at 14.79 out of 53 indicators.

Enforcement; and Membership and Ratification of International Treaties

37. Effective border measures: and 50. At least one post-TRIPS FTA with substantive IP provisions and chapters in line with international best practices: As noted in last year's edition, before 2016 and the enactment of the Código Ingenios, Ecuadorian border officials not only had the power to seize suspected IP-infringing goods but were legally obliged and compelled to do so with failure to act constituting a potential offense. Article 342 of the Intellectual Property Law, 2006_13, stated that "The Ecuadorian Customs Corporation and all those that have control over the entry or exit of goods into or from Ecuador shall be obliged to prevent the entry or export of goods that in any way infringe intellectual property rights. Where, at the request of an interested party, they do not prevent the entry or export of such goods, they shall be considered accessories to the offense committed, without prejudice to the relevant administrative penalty." This right to act was granted through both a rightsholder notification process and through ex officio powers.

Article 575 of the *Código Ingenios*, as well as Articles 458 to 465 of the 2020 Implementing Regulations, removed this right of action from customs officials and instead transferred both the notification process and *ex officio* authority to the national IP office SENADI. National customs officers are the first line of defense against the menace of counterfeit goods. It is essential that they can act expeditiously and effectively against suspected IP-infringing goods. As Ecuadorian customs and border officials continue to lack this power of action, the score for this indicator was reduced in last year's edition to 0.

In 2023, Ecuador concluded a new Trade Association Agreement (Acuerdo de Asociación Comercial) with Costa Rica. This agreement was ratified by both economies and came into effect in 2024. Chapter 16 of this agreement is dedicated to IP rights. This is a positive feature of the agreement, and both parties should be congratulated for recognizing the importance of IP-intensive industries and the centrality of IP rights to future trade and economic development in all economies. As has been noted in the Index, this is not always the case. Many 21st-century post-TRIPS FTAs do not include a dedicated IP chapter or skirt meaningful provisions on IP rights altogether. Unfortunately, the agreement does not conform to the standards of a modern post-TRIPS FTA because the IP chapters do not include substantive IP provisions in line with international best practices and identified in the Index. Indeed, much of the IP chapter is linked to rights defined and specified in TRIPS. When signed in 1994, the **TRIPS** Agreement represented an unprecedented commitment and recognition of minimum global IP standards. But 30 years after Marrakesh, TRIPS is outdated and no longer represents or includes all the standards and protections that a modern, innovation-based economy needs.

In terms of specific features and IP rights missing from the agreement, there is no reference to patent protection or related rights; copyright provisions are relatively limited with no reference to the challenges that the online environment or infringement represents to rightsholders; and there is no or limited reference to sector-specific provisions, including biopharmaceutical IP rights such as RDP and patent term restoration. On a positive note, the agreement includes a clear and unambiguous requirement that border officials in all contracting parties have the right to take ex officio action against suspected infringing goods, including against goods in transit, destined for export, and not intended for the domestic market. Specifically, Article 16.12(6) states, "Each Party shall provide that the competent authorities are empowered to initiate border measures ex officio, without the need for a formal request from the right holder or a third party, when there are reasons to believe or suspect that the goods being imported, exported or in transit are counterfeit or pirated." Should Ecuador fully transpose and implement this requirement, its score for this indicator would increase. The Index will monitor this in 2025.

Incentives for Cutting-Edge Innovation

44. Special market exclusivity incentives for orphan medicinal product development; 45. Special market exclusivity incentives for orphan medicinal product development, term of protection; and 46. Restrictions on the effective use of existing market exclusivity incentives for orphan medicinal product development:

The national health law (Ley 67 Organica de Salud) includes five separate articles dedicated to defining the rights of patients with rare diseases and accompanying obligations on behalf of the government and relevant national authorities. Specifically, the law outlines an obligation on the part of the Ministry of Health and related health service authorities to provide for medical treatment, access to medicines, the creation of a national registry, the timely supply and distribution of relevant treatments, and incentives for R&D. The law does not include any reference to or definition of any special IP-based market exclusivity incentives for orphan medicinal product development.